Free Trial

Truist Financial Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

Genmab A/S logo with Medical background

Genmab A/S (NASDAQ:GMAB - Get Free Report) had its target price raised by analysts at Truist Financial from $45.00 to $46.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's target price would indicate a potential upside of 113.41% from the stock's current price.

Several other research analysts have also issued reports on the company. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. HC Wainwright reiterated a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Finally, Wall Street Zen downgraded Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.80.

Read Our Latest Analysis on GMAB

Genmab A/S Trading Up 1.4%

NASDAQ GMAB traded up $0.31 on Tuesday, hitting $21.56. 598,552 shares of the company's stock were exchanged, compared to its average volume of 1,511,996. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $28.56. The stock has a market cap of $13.83 billion, a price-to-earnings ratio of 12.25, a P/E/G ratio of 6.69 and a beta of 0.94. The stock has a 50-day moving average of $21.01 and a 200-day moving average of $20.73.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. As a group, analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Trading of Genmab A/S

Several large investors have recently made changes to their positions in GMAB. Bank of New York Mellon Corp lifted its position in Genmab A/S by 4.0% in the 4th quarter. Bank of New York Mellon Corp now owns 71,623 shares of the company's stock valued at $1,495,000 after acquiring an additional 2,749 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Genmab A/S by 134.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,177 shares of the company's stock valued at $1,277,000 after acquiring an additional 35,073 shares in the last quarter. Raymond James Financial Inc. bought a new position in Genmab A/S in the 4th quarter valued at about $2,463,000. Callan Family Office LLC bought a new position in Genmab A/S in the 4th quarter valued at about $225,000. Finally, Sequoia Financial Advisors LLC lifted its position in Genmab A/S by 27.8% in the 4th quarter. Sequoia Financial Advisors LLC now owns 22,204 shares of the company's stock valued at $463,000 after acquiring an additional 4,835 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines